The cell cycle and cancer

Journal of Pathology

Volumn 226, Issue 2, 2012, Pages 352-364

  Williams, Gareth H ^a,b   Stoeber, Kai ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

biomarker; cancer; cell cycle; DNA replication; geminin; MCM; mitosis; phosphohistone; therapy

Indexed keywords

B RAF KINASE; CISPLATIN; DNA; DOCETAXEL; FLUOROURACIL; GEMCITABINE; GEMININ; HISTONE; IRINOTECAN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN; VINCRISTINE;

BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL POPULATION; CELL PROLIFERATION; DNA REPLICATION; DNA SYNTHESIS; DRUG TARGETING; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMAN; KIDNEY CANCER; LUNG CANCER; MITOSIS; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; DNA REPLICATION; EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHOTRANSFERASES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 82755177826     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3022     Document Type: Review

References (135)

1. Potten CS, Loeffler M,. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001-1020. (Pubitemid 120009472)
2. Hall PA, Watt FM,. Stem cells: the generation and maintenance of cellular diversity. Development 1989; 106: 619-633. (Pubitemid 19221519)
3. Williams GH, Stoeber K,. Cell cycle markers in clinical oncology. Curr Opin Cell Biol 2007; 19: 672-679. (Pubitemid 350216427)
4. Murray A, Hunt T,. The Cell Cycle: An Introduction. Oxford University Press: New York, 1993.
5. 1 leading to proliferation or quiescence of Swiss 3T3 cells. Proc Natl Acad Sci USA 1985; 82: 5365-5369. (Pubitemid 15012107)
6. Malumbres M, Barbacid M,. Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 2006; 9: 2-4. (Pubitemid 43069503)
7. Planas-Silva MD, Weinberg RA,. The restriction point and control of cell proliferation. Curr Opin Cell Biol 1997; 9: 768-772. (Pubitemid 27517264)
8. Nigg EA,. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001; 2: 21-32. (Pubitemid 33676958)
9. Hartwell LH, Weinert TA,. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246: 629-634. (Pubitemid 19283354)
10. Bartek J, Lukas C, Lukas J,. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004; 5: 792-804. (Pubitemid 39336273)
11. Musacchio A, Salmon ED,. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8: 379-393. (Pubitemid 46643240)
12. Malumbres M, Barbacid M,. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-166.
13. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
14. Harbour JW, Dean DC,. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000; 14: 2393-2409.
15. Zhang J, Yang PL, Gray NS,. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
16. Freier K, Joos S, Flechtenmacher C, et al., Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003; 63: 1179-1182. (Pubitemid 36348691)
17. Huang ZY, Baldwin RL, Hedrick NM, et al., Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. Oncogene 2002; 21: 1325-1334. (Pubitemid 34214498)
18. Malumbres M, Barbacid M,. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222-231. (Pubitemid 33741897)
19. Perou CM, Sorlie T, Eisen MB, et al., Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
20. van't Veer LJ, Dai H, van de Vijver MJ, et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536. (Pubitemid 34130608)
21. van't Veer LJ, Bernards R,. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452: 564-570. (Pubitemid 351483370)
22. Michiels S, Koscielny S, Hill C,. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488-492. (Pubitemid 40215731)
23. Dunkler D, Michiels S, Schemper M,. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 2007; 43: 745-751. (Pubitemid 46502906)
24. Mackay A, Weigelt B, Grigoriadis A, et al., Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst 2011; 103: 662-673.
25. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al., Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007; 8: 1079-1087. (Pubitemid 350182954)
26. Hannemann J, Oosterkamp HM, Bosch CA, et al., Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23: 3331-3342.
27. Sotiriou C, Piccart MJ,. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7: 545-553. (Pubitemid 46985399)
28. Weinstein IB, Joe AK,. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3: 448-457. (Pubitemid 44203817)
29. Stratton MR, Campbell PJ, Futreal PA,. The cancer genome. Nature 2009; 458: 719-724.
30. Sierra JR, Cepero V, Giordano S,. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010; 9: 75.
31. Wick W, Puduvalli VK, Chamberlain MC, et al., Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28: 1168-1174.
32. Jain RK, Duda DG, Clark JW, et al., Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40. (Pubitemid 43108832)
33. Rini BI, Halabi S, Rosenberg JE, et al., Phase III trial of bevacizumab plus interferon-α versus interferon-α monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143.
34. Fisher WE,. The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark. World J Surg 2011; 35: 1766-1769.
35. Batchelor T, Mulholland P, Neyns B, et al., The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study. Neuro-Oncology 2010; 12: iv69-78.
36. AstraZeneca. AstraZeneca provides update on cediranib (RECENTIN, AZD2171) clinical development programme: [accessed 27 February 2008].
37. AstraZeneca. AstraZeneca announces results of recentin HORIZON II Phase III trial in metastatic colorectal cancer: [accessed 28 May 2010].
38. AstraZeneca. Phase II data contributes to understanding of cediranib in recurrent glioblastoma: [accessed 14 May 2010].
39. Williams GH, Romanowski P, Morris L, et al., Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA 1998; 95: 14932-14937. (Pubitemid 29003734)
40. Williams G, Stoeber K,. Clinical applications of a novel mammalian cell-free DNA replication system. Br J Cancer 1999; 80 (suppl 1): 20-24. (Pubitemid 29389602)
41. Gonzalez MA, Tachibana KE, Laskey RA, et al., Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer 2005; 5: 135-141. (Pubitemid 40215861)
42. Blow JJ, Gillespie PJ,. Replication licensing and cancer-a fatal entanglement? Nat Rev Cancer 2008; 8: 799-806.
43. Blow JJ, Hodgson B,. Replication licensing-defining the proliferative state? Trends Cell Biol 2002; 12: 72-78.
44. Machida YJ, Hamlin JL, Dutta A,. Right place, right time, and only once: replication initiation in metazoans. Cell 2005; 123: 13-24. (Pubitemid 41414525)
45. Masai H, Matsumoto S, You Z, et al., Eukaryotic chromosome DNA replication: where, when, and how? Annu Rev Biochem 2010; 79: 89-130.
46. Sclafani RA, Holzen TM,. Cell cycle regulation of DNA replication. Annu Rev Genet 2007; 41: 237-280.
47. Labib K, Diffley JF,. Is the MCM2-7 complex the eukaryotic DNA replication fork helicase? Curr Opin Genet Dev 2001; 11: 64-70. (Pubitemid 32119280)
48. Blow JJ, Tanaka TU,. The chromosome cycle: coordinating replication and segregation. Second in the cycles review series. EMBO Rep 2005; 6: 1028-1034. (Pubitemid 41637646)
49. Perkins G, Diffley JF,. Nucleotide-dependent prereplicative complex assembly by Cdc6p, a homolog of eukaryotic and prokaryotic clamp-loaders. Mol Cell 1998; 2: 23-32. (Pubitemid 128378963)
50. Labib K,. How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes Dev 2010; 24: 1208-1219.
51. Sheu YJ, Stillman B,. Cdc7-Dbf4 phosphorylates MCM proteins via a docking site-mediated mechanism to promote S phase progression. Mol Cell 2006; 24: 101-113. (Pubitemid 44466677)
52. Sheu YJ, Stillman B,. The Dbf4-Cdc7 kinase promotes S phase by alleviating an inhibitory activity in Mcm4. Nature 2010; 463: 113-117.
53. Montagnoli A, Valsasina B, Brotherton D, et al., Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem 2006; 281: 10281-10290. (Pubitemid 43864566)
54. Gambus A, Jones RC, Sanchez-Diaz A, et al., GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nat Cell Biol 2006; 8: 358-366.
55. Labib K, Gambus A,. A key role for the GINS complex at DNA replication forks. Trends Cell Biol 2007; 17: 271-278. (Pubitemid 46829847)
56. Moyer SE, Lewis PW, Botchan MR,. Isolation of the Cdc45/Mcm2-7/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase. Proc Natl Acad Sci USA 2006; 103: 10236-10241. (Pubitemid 44051150)
57. Blow JJ, Dutta A,. Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol 2005; 6: 476-486. (Pubitemid 40780559)
58. Li X, Zhao Q, Liao R, et al., The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J Biol Chem 2003; 278: 30854-30858. (Pubitemid 36994595)
59. Tada S, Li A, Maiorano D, et al., Repression of origin assembly in metaphase depends on inhibition of RLF-B/Cdt1 by geminin. Nat Cell Biol 2001; 3: 107-113. (Pubitemid 32118362)
60. Wohlschlegel JA, Kutok JL, Weng AP, et al., Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am J Pathol 2002; 161: 267-273. (Pubitemid 34760792)
61. Okorokov AL, Orlova EV, Kingsbury SR, et al., Molecular structure of human geminin. Nat Struct Mol Biol 2004; 11: 1021-1022. (Pubitemid 39315308)
62. Stoeber K, Tlsty TD, Happerfield L, et al., DNA replication licensing and human cell proliferation. J Cell Sci 2001; 114: 2027-2041. (Pubitemid 32586628)
63. Eward KL, Obermann EC, Shreeram S, et al., DNA replication licensing in somatic and germ cells. J Cell Sci 2004; 117: 5875-5886. (Pubitemid 40123953)
64. Stoeber K, Mills AD, Kubota Y, et al., Cdc6 protein causes premature entry into S phase in a mammalian cell-free system. EMBO J 1998; 17: 7219-7229. (Pubitemid 29002691)
65. Mailand N, Diffley JF,. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 2005; 122: 915-926. (Pubitemid 41345208)
66. Barkley LR, Hong HK, Kingsbury SR, et al., Cdc6 is a rate-limiting factor for proliferative capacity during HL60 cell differentiation. Exp Cell Res 2007; 313: 3789-3799. (Pubitemid 47464231)
67. Musahl C, Holthoff HP, Lesch R, et al., Stability of the replicative Mcm3 protein in proliferating and differentiating human cells. Exp Cell Res 1998; 241: 260-264. (Pubitemid 28366601)
68. Freeman A, Morris LS, Mills AD, et al., Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999; 5: 2121-2132. (Pubitemid 29399268)
69. Going JJ, Keith WN, Neilson L, et al., Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 2002; 50: 373-377. (Pubitemid 34161054)
70. Alison MR, Hunt T, Forbes SJ,. Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut 2002; 50: 290-291. (Pubitemid 34161038)
71. Ramnath N, Hernandez FJ, Tan DF, et al., MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 2001; 19: 4259-4266. (Pubitemid 33081644)
72. Meng MV, Grossfeld GD, Williams GH, et al., Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 2001; 7: 2712-2718. (Pubitemid 32911375)
73. Kayes OJ, Loddo M, Patel N, et al., DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res 2009; 15: 7335-7344.
74. Kulkarni AA, Loddo M, Leo E, et al., DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin Cancer Res 2007; 13: 6153-6161. (Pubitemid 350075075)
75. Dudderidge TJ, Stoeber K, Loddo M, et al., Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005; 11: 2510-2517. (Pubitemid 40569447)
76. Korkolopoulou P, Givalos N, Saetta A, et al., Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Hum Pathol 2005; 36: 899-907. (Pubitemid 41187909)
77. Gonzalez MA, Pinder SE, Callagy G, et al., Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 2003; 21: 4306-4313. (Pubitemid 46628462)
78. Rhodes DR, Yu J, Shanker K, et al., Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004; 101: 9309-9314. (Pubitemid 38812872)
79. Yan Z, DeGregori J, Shohet R, et al., Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA 1998; 95: 3603-3608. (Pubitemid 28173174)
80. Yoshida K, Inoue I,. Regulation of Geminin and Cdt1 expression by E2F transcription factors. Oncogene 2004; 23: 3802-3812. (Pubitemid 38725693)
81. Ohtani K, Iwanaga R, Nakamura M, et al., Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene 1999; 18: 2299-2309. (Pubitemid 29192707)
82. Yoshida K, Inoue I,. Expression of MCM10 and TopBP1 is regulated by cell proliferation and UV irradiation via the E2F transcription factor. Oncogene 2004; 23: 6250-6260. (Pubitemid 39215295)
83. Yamada M, Sato N, Taniyama C, et al., A 63-base pair DNA segment containing an Sp1 site but not a canonical E2F site can confer growth-dependent and E2F-mediated transcriptional stimulation of the human ASK gene encoding the regulatory subunit for human Cdc7-related kinase. J Biol Chem 2002; 277: 27668-27681. (Pubitemid 34966710)
84. Liontos M, Koutsami M, Sideridou M, et al., Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res 2007; 67: 10899-10909. (Pubitemid 350145919)
85. Arentson E, Faloon P, Seo J, et al., Oncogenic potential of the DNA replication licensing protein CDT1. Oncogene 2002; 21: 1150-1158. (Pubitemid 34185231)
86. Gonzalez S, Klatt P, Delgado S, et al., Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 2006; 440: 702-706.
87. Seo J, Chung YS, Sharma GG, et al., Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53. Oncogene 2005; 24: 8176-8186. (Pubitemid 41759816)
88. Honeycutt KA, Chen Z, Koster MI, et al., Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis. Oncogene 2006; 25: 4027-4032. (Pubitemid 44024865)
89. Shima N, Alcaraz A, Liachko I, et al., A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nat Genet 2007; 39: 93-98. (Pubitemid 46026507)
90. Pruitt SC, Bailey KJ, Freeland A,. Reduced Mcm2 expression results in severe stem/progenitor cell deficiency and cancer. Stem Cells 2007; 25: 3121-3132. (Pubitemid 350294438)
91. Kelly D, Kincaid E, Fansler Z, et al., Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx C). Cancer 2006; 108: 494-500. (Pubitemid 46076970)
92. Shroyer KR, Homer P, Heinz D, et al., Validation of a novel immunocytochemical assay for topoisomerase IIα and minichromosome maintenance protein 2 expression in cervical cytology. Cancer 2006; 108: 324-330. (Pubitemid 44583712)
93. + after HPV primary screening. Cancer Epidemiol Biomarkers Prev 2011; 20: 628-637.
94. Ayaru L, Stoeber K, Webster GJ, et al., Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates. Br J Cancer 2008; 98: 1548-1554. (Pubitemid 351652335)
95. Dudderidge TJ, Kelly JD, Wollenschlaeger A, et al., Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer 2010; 103: 701-707.
96. Williams GH, Swinn R, Prevost AT, et al., Diagnosis of oesophageal cancer by detection of minichromosome maintenance 5 protein in gastric aspirates. Br J Cancer 2004; 91: 714-719. (Pubitemid 39141630)
97. Stoeber K, Halsall I, Freeman A, et al., Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. Lancet 1999; 354: 1524-1525. (Pubitemid 29502109)
98. Stoeber K, Swinn R, Prevost AT, et al., Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J Natl Cancer Inst 2002; 94: 1071-1079. (Pubitemid 34830727)
99. Fletcher AH, Barklow TA, Murphy NJ, et al., ProExC triage of atypical glandular cells on liquid-based cervical cytology specimens. J Low Genit Tract Dis 2011; 15: 6-10.
100. Tambouret RH, Misdraji J, Wilbur DC,. Longitudinal clinical evaluation of a novel antibody cocktail for detection of high-grade squamous intraepithelial lesions on cervical cytology specimens. Arch Pathol Lab Med 2008; 132: 918-925. (Pubitemid 351918696)
101. Siddiqui MT, Cohen C, Nassar A,. Detecting high-grade cervical disease on ASC-H cytology: role of BD ProEx C and Digene Hybrid Capture II HPV DNA testing. Am J Clin Pathol 2008; 130: 765-770.
102. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
103. Coindre JM,. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med 2006; 130: 1448-1453.
104. Hugh J, Hanson J, Cheang MC, et al., Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
105. Penault-Llorca F, Andre F, Sagan C, et al., Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2809-2815.
106. Yerushalmi R, Woods R, Ravdin PM, et al., Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-183.
107. Hook SS, Lin JJ, Dutta A,. Mechanisms to control rereplication and implications for cancer. Curr Opin Cell Biol 2007; 19: 663-671. (Pubitemid 350216429)
108. Crosio C, Fimia GM, Loury R, et al., Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002; 22: 874-885. (Pubitemid 34053065)
109. Wei Y, Yu L, Bowen J, et al., Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 1999; 97: 99-109. (Pubitemid 29165893)
110. Loddo M, Kingsbury SR, Rashid M, et al., Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 2009; 100: 959-970.
111. Rodriguez-Acebes S, Proctor I, Loddo M, et al., Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Am J Pathol 2010; 177: 2034-2045.
112. Whitfield ML, Sherlock G, Saldanha AJ, et al., Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002; 13: 1977-2000. (Pubitemid 34651487)
113. Wirapati P, Sotiriou C, Kunkel S, et al., Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
114. Paik S, Shak S, Tang G, et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
115. Proctor I, Stoeber K, Williams GH,. Biomarkers in bladder cancer. Histopathology 2010; 57: 1-13.
116. Ellis P, Barrett-Lee P, Johnson L, et al., Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009; 373: 1681-1692.
117. Poole CJ, Hiller L, Howard HC, et al., tAnGo: a randomized Phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/ cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). J Clin Oncol 2008; 26:Abstract 506.
118. Kulkarni AA, Kingsbury SR, Tudzarova S, et al., Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clin Cancer Res 2009; 15: 2417-2425.
119. Rinehart J, Adjei AA, Lorusso PM, et al., Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 4456-4462. (Pubitemid 41185111)
120. Wilhelm SM, Carter C, Tang L, et al., BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109. (Pubitemid 39331023)
121. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
122. Bild AH, Potti A, Nevins JR,. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 2006; 6: 735-741. (Pubitemid 44304232)
123. Bild AH, Yao G, Chang JT, et al., Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357. (Pubitemid 43128862)
124. Huang E, Ishida S, Pittman J, et al., Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet 2003; 34: 226-230. (Pubitemid 36666937)
125. Shreeram S, Sparks A, Lane DP, et al., Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene 2002; 21: 6624-6632. (Pubitemid 35177041)
126. Montagnoli A, Tenca P, Sola F, et al., Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res 2004; 64: 7110-7116. (Pubitemid 39331024)
127. Montagnoli A, Valsasina B, Croci V, et al., A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 2008; 4: 357-365. (Pubitemid 351693995)
128. Ge XQ, Jackson DA, Blow JJ,. Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress. Genes Dev 2007; 21: 3331-3341. (Pubitemid 350277759)
129. Tudzarova S, Trotter MW, Wollenschlaeger A, et al., Molecular architecture of the DNA replication origin activation checkpoint. EMBO J 2010; 29: 3381-3394.
130. Swords R, Mahalingam D, O'Dwyer M, et al., Cdc7 kinase-a new target for drug development. Eur J Cancer 2010; 46: 33-40.
131. Montagnoli A, Moll J, Colotta F,. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res 2010; 16: 4503-4508.
132. Im JS, Lee JK,. ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7. J Biol Chem 2008; 283: 25171-25177.
133. Kim JM, Kakusho N, Yamada M, et al., Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint. Oncogene 2008; 27: 3475-3482. (Pubitemid 351769309)
134. Matsumoto S, Shimmoto M, Kakusho N, et al., Hsk1 kinase and Cdc45 regulate replication stress-induced checkpoint responses in fission yeast. Cell Cycle 2010; 9: 4627-4637.
135. Blagosklonny MV, Pardee AB,. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61: 4301-4305. (Pubitemid 32685747)